1. Health technology

  2. •

    Biotechnology
Lonza Group AG

Lonza Group AG

613.80
EUR
-0.20
(-0.03%)
41.67BMarket Cap
Lonza Group AG
MIL:1LONN
(Euronext Milan)

Recent

price

613.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CHF
47.37
48.29
70.22
63.91
64.86
67.4
72.85
67
74.48
56.77
60.59
72.84
83.83
91.23
76.99
93.27
- -
Revenue per Share
5.02
2.76
3.11
1.55
4.22
4.91
5.31
10.42
7.51
8.7
11.68
39.65
16.37
8.88
8.94
-3.93
- -
Basic EPS, GAAP
2.74
-0.83
7.16
5.55
5.4
8.45
6.81
5.75
6.81
2.42
2.11
-1.67
-11.48
-3.99
-2.01
-3.1
- -
Free Cash Flow per Basic Share
1.63
1.99
1.99
2
2
2.32
2.31
2.36
2.77
2.78
2.77
3.03
3.07
3.57
4.05
4.03
- -
Dividend per Share
42.13
38.37
37.48
37.89
37.93
37.83
40.39
82.61
83.75
87.42
91.74
131.42
142.66
131.07
129.3
113.29
116.26
Book Value per Share
30.59
2.3
3.1
4.94
2.19
3.26
0.82
-21.15
-11.34
-3.1
14.85
58.09
74.08
65.34
54.85
80.54
83.63
Tangible Book Value per Share
57
56
56
56
56
56
57
68
74
74
74
74
74
74
71
70
70
Basic Weighted Avg Shares
2,680
2,692
3,925
3,584
3,640
3,803
4,132
4,548
5,542
4,207
4,508
5,409
6,223
6,717
5,480
6,531
- -
Sales/Revenue/Turnover
13.96
9.7
8.66
7.06
11.62
11.39
12.92
14.31
16.37
20.2
20.67
15.29
21.81
13
16.04
20.79
- -
Operating Margin (%)
273
276
304
309
299
300
307
411
526
544
526
522
596
621
647
813
- -
Depreciation Expense
284
154
174
87
237
277
301
707
559
645
869
2,944
1,215
654
636
-275
- -
Net Income, GAAP
13.94
12
17.14
17.14
15.05
18.77
19.3
- -
18.34
9.87
8.84
10.92
15.88
17.09
14.97
17.44
- -
Effective Tax Rate (%)
10.6
5.72
4.43
2.43
6.51
7.28
7.28
15.55
10.09
15.33
19.28
54.43
19.52
9.74
11.61
-4.21
- -
Profit Margin (%)
336
866
661
655
323
268
433
560
1,134
365
1,704
3,585
2,637
2,139
1,861
3,209
2,764
Working Capital
910
2,725
2,427
2,245
1,693
1,414
1,571
3,730
3,621
2,985
2,994
2,530
1,855
2,905
4,608
4,197
3,393
LT Debt
2,387
2,137
2,102
2,126
2,130
2,135
2,302
6,181
6,290
6,565
6,884
9,823
10,665
9,512
9,388
7,966
8,152
Total Equity
8.24
5.09
11.09
4.32
7.89
8.11
9.34
- -
6.44
7.08
7.69
6.44
9.96
5.6
5.65
7.53
- -
Return on Invested Capital (%)
8.26
4.44
5.46
3.71
6.73
8.12
8.78
- -
6.11
6.87
8.85
25.87
9.8
5.64
5.55
-1.04
- -
Return on Capital (%)
12.05
6.81
8.21
4.11
11.14
12.99
13.57
16.76
9.05
10.15
13.06
35.54
11.94
6.52
6.77
-3.19
- -
Return on Common Equity (%)

Capital Structure

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
415
343
774
LT Borrowings
4,199
3,876
3,393
LT Finance Leases
- -
321
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
70
70
70
Market Capitalization
39,643
37,667
38,457

Working Capital

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
4,589
6,834
6,936
Cash, Cash Equivalents & STI
907
719
487
Accounts Receivable, Net
1,805
1,062
1,920
Inventories
1,843
1,680
1,880
Total Current Liabilities
3,151
3,625
4,172
Payables & Accruals
- -
- -
- -
ST Debt
415
343
774
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.13%
4.8%
-15.15%
Free Cash Flow
27.8%
68.6%
51.75%
Net Income, GAAP
16.06%
-2.42%
-143.24%
Sales/Revenue/Turnover
6.74%
8.75%
19.18%
Total Cash Common Dividend
- -
6.67%
-2.08%

Quarterly Revenue

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
5,480
2025
- -
- -
- -
- -
6,531
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
8.94
2025
- -
- -
- -
- -
-3.93
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
4.05
2025
- -
- -
- -
- -
4.03
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business

Company News

Company News APIChatGPT

  • seekingalpha.com

    Lonza Group AG (LZAGY) Analyst/Investor Day Transcript

  • defenseworld.net

    Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Update

  • seekingalpha.com

    Lonza Group AG (LZAGY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  • seekingalpha.com

    Lonza: Strong H1 Execution, Higher Guidance Means Higher Upside

  • seekingalpha.com

    Lonza Group AG (LZAGY) Q2 2026 Earnings Call Transcript

  • zacks.com

    PAHC or LZAGY: Which Is the Better Value Stock Right Now?

  • seekingalpha.com

    Lonza Group AG (LZAGY) Q1 2026 Earnings Call Transcript

  • businesswire.com

    Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

  • seekingalpha.com

    Lonza: Structural Growth Intact, CHI Exit Strengthens Focus, Recent Weakness Reinforces Entry Opportunity

  • seekingalpha.com

    Lonza Group AG (LZAGY) Discusses Divestment of Capsules and Health Ingredients Business and Focus on CDMO Transformation Transcript

  • businesswire.com

    Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG

  • seekingalpha.com

    Lonza Group Continues To Leverage Biopharma's Optimization Push

  • seekingalpha.com

    Lonza Group AG (LZAGY) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Lonza Group AG (LZAGY) Q3 2025 Earnings Call Transcript

  • zacks.com

    PHG vs. LZAGY: Which Stock Is the Better Value Option?

  • zacks.com

    Here's Why Lonza Group (LZAGY) Is a Great 'Buy the Bottom' Stock Now

  • seekingalpha.com

    Lonza Group AG (LZAGY) Q2 2025 Earnings Call Transcript

  • zacks.com

    Lonza Group (LZAGY) Upgraded to Strong Buy: Here's Why

  • seekingalpha.com

    Lonza Group AG (LZAGY) Q1 2025 Earnings Call Transcript

  • zacks.com

    Lonza Group Ag (LZAGY) is a Great Momentum Stock: Should You Buy?